https://m2.mtmt.hu/ hun 2026-10-24 12:53 JournalArticle 32049273 VALIDATED true Export Date: 9 August 2021 CODEN: POREF 0 false 2026-10-21T10:21:01.469+0000 2025-11-03T12:41:54.331+0000 2021-06-01T11:41:54.356+0000 true 10074913 Sághi-Keszthelyi Anna /api/admin/10074913 Admin Sághi-Keszthelyi Anna (SE_KK_Admin5_SKA, admin) true 2026-07-14T11:36:09.226+0000 2026-07-14T11:36:09.226+0000 2022-10-11T11:47:18.412+0000 true 10067876 Ladányi Gusztáv /api/admin/10067876 Admin Ladányi Gusztáv (MTMT API user, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Boér, K. true true /api/journal/1035680 REVIEWED PATHOLOGY AND ONCOLOGY RESEARCH 1219-4956 1532-2807 true false 1035680 false 1035680 true 1219-4956 1532-2807 Journal FOREIGN_AND_HUNGARIAN 27 1609785 1609785 9 2021 Purpose: The neoadjuvant use of pertuzumab and trastuzumab with chemotherapy improves the pathologic complete response (pCR) in early HER2+ breast cancer. The aim of this study was to determine the pCR rate obtained with dual HER2 blockade in routine clinical practice. The secondary and tertiary objective was to investigate the impact of neoadjuvant systemic therapy (NST) on performing breast-conserving surgery and survival data. Methods: This was a multicentre, retrospective, observational study in patients with stage II and III HER2+ early breast cancer who received pertuzumab and trastuzumab-based NST. Data were collected from patients’ medical records. Results: Eighty-two patients were included in the study treated in 8 cancer centers in Hungary between March 2015 and January 2020. The study included women with a median age of 50.3 years. The majority of the patients (95%) received a sequence of anthracycline-based chemotherapy followed by docetaxel. pCR was achieved in 54% of the cases. As a result of NST a significant increase of conservative breast surgeries (33% vs. 3.6% planned, p = 0.0001) was observed. Ki67 expression and neutrophil-to-lymphocyte ratio (NLR) significantly predicted pCR. None of the variables were independent predictors of DFS. Conclusion: The pCR rate achieved in our study demonstrates the reproducibility of trial data in a real-world population. The rate of breast-conserving surgery was significantly increased. © Copyright © 2021 Boér, Kahán, Landherr, Csőszi, Máhr, Ruzsa, Horváth, Budai and Rubovszky. true true 2021 true true true false true false GREEN 2026-10-21 true http://publicatio.bibl.u-szeged.hu/35999 22 0 21 21 0 21 21 19 17 21 21 21 21 22 0 0 22 22 21 21 0 1 1 Folyóiratcikk Journal Article 24 21 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 1 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2021 0 1 1 1 1 2022 0 6 6 6 6 2023 0 5 5 5 5 2024 0 3 3 3 3 2025 0 4 4 4 4 2026 0 3 3 3 3 Q2 false false false false 2021-05-31T12:25:35.698+0000 Onkológiai Tanszék (SE / AOK / K); Onkoterápiás Klinika (SZTE / SZAOK); Országos Onkológiai Intézet; Uzsoki Utcai Kórház 7 30 4 9 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 96489988 /api/authorship/96489988 Boér, K. [Boér, Katalin (Klinikai Orvostud...), szerző] 1 0.11111111 true false false Author 10048974 /api/author/10048974 Boér Katalin (Klinikai Orvostudomány) Boér Katalin true 10048974 true Boér K. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96489989 /api/authorship/96489989 Kahán, Z. [Kahán, Zsuzsanna (Elméleti orvostud...), szerző] Onkoterápiás Klinika (SZTE / SZAOK) 2 0.11111111 false false false Author 10013805 /api/author/10013805 Kahán Zsuzsanna (Elméleti orvostudomány) Kahán Zsuzsanna true 10013805 true Kahán Z. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96489990 /api/authorship/96489990 Landherr, L. [Landherr, László (sugárterápia, kli...), szerző] Uzsoki Utcai Kórház 3 0.111 false false false Author 10036736 /api/author/10036736 Landherr László (sugárterápia, klinikai onkológia) Landherr László true 10036736 true Landherr L. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96489991 /api/authorship/96489991 Csőszi, T. 4 0.11111111 false false false Csőszi T. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96489992 /api/authorship/96489992 Máhr, K. [Máhr, Károly (Onkológia), szerző] 5 0.11111111 false false false Author 10035708 /api/author/10035708 Máhr Károly (Onkológia) Máhr Károly true 10035708 true Máhr K. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96489993 /api/authorship/96489993 Ruzsa, Á. 6 0.11111111 false false false Ruzsa Á. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96489994 /api/authorship/96489994 Horváth, Z. [Horváth, Zsolt (Onkológia), szerző] 7 0.111 false false false Author 10026959 /api/author/10026959 Horváth Zsolt (Onkológia) Horváth Zsolt true 10026959 true Horváth Z. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96489995 /api/authorship/96489995 Budai, B. [Budai, Barna (Onkológia), szerző] Országos Onkológiai Intézet 8 0.111 false false false Author 10038262 /api/author/10038262 Budai Barna (Onkológia) Budai Barna true 10038262 true Budai B. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96489996 /api/authorship/96489996 Rubovszky, G. ✉ [Rubovszky, Gábor (klinikai onkológia), szerző] Országos Onkológiai Intézet; Onkológiai Tanszék (SE / AOK / K) 9 0.111 false true true Author 10060070 /api/author/10060070 Rubovszky Gábor (klinikai onkológia) Rubovszky Gábor true 10060070 true Rubovszky G. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 18873813 /api/publicationidentifier/18873813 DOI: 10.3389/pore.2021.1609785 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.3389/pore.2021.1609785 https://doi.org/10.3389/pore.2021.1609785 false true PublicationIdentifier 18873814 /api/publicationidentifier/18873814 WoS: 000651213200001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000651213200001 https://www.webofscience.com/wos/woscc/full-record/000651213200001 false true PublicationIdentifier 18873812 /api/publicationidentifier/18873812 Scopus: 85106039535 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85106039535 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85106039535 false true PublicationIdentifier 23376197 /api/publicationidentifier/23376197 PubMed: 34257621 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 34257621 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34257621&dopt=Abstract true true PublicationIdentifier 28391158 /api/publicationidentifier/28391158 SZTE Publicatio: 35999 SwordSource 90 /api/publicationsource/90 SZTE Publicatio PublicationSourceType 10007 /api/publicationsourcetype/10007 Repozitórium true true true SZTE Publicatio SZTE Publicatio http://publicatio.bibl.u-szeged.hu/@@@ true true 90 true GREEN true IDENTICAL 35999 http://publicatio.bibl.u-szeged.hu/35999 false true Keyword 1161026 /api/keyword/1161026 Early breast cancer true 1161026 true Keyword 1190953 /api/keyword/1190953 Neoadjuvant systemic therapy true 1190953 true Keyword 1349357 /api/keyword/1349357 Breast-conserving surgery true 1349357 true Keyword 1562141 /api/keyword/1562141 PATHOLOGICAL COMPLETE RESPONSE true true Keyword 1629870 /api/keyword/1629870 Neutrophil-to-lymphocyte ratio true true Keyword 1900903 /api/keyword/1900903 HER2+ true true SjrRating 11225850 /api/sjrrating/11225850 sjr:Q2 (2021) Scopus - Medicine (miscellaneous) PATHOLOGY AND ONCOLOGY RESEARCH 1219-4956 1532-2807 968 0.49 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2701 /api/classificationexternal/2701 Scopus - Medicine (miscellaneous) true 2701 true Q2 DIRECT true true Reference 20952088 /api/reference/20952088 1. Bae, S.J., Yoon, C.-I., Park, S.E., Cha, C.H., Kim, D., Lee, J., A Neutrophil to Lymphocyte Ratio Is Predictive of Response to Neoadjuvant HER2-Targeted Therapies in the Patients with HER2-Positive Breast Cancer (2019) J. Clin. Oncol, 37 (15_Suppl. l), p. 587 1 false true Reference 20952087 /api/reference/20952087 2. Muñoz-Montaño, W., Cabrera-Galeana, P., Alvarado-Miranda, A., Villarreal-Garza, C., Mohar, A., Olvera, A., Prognostic Value of the Pretreatment Neutrophil-To-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer during Neoadjuvant Systemic Treatment (2020) Clin Breast Cancer, 20, pp. 307-316 2 false true Reference 20952086 /api/reference/20952086 3. Chang, Y.-K., Co, M., Kwong, A., Conversion Rate from Mastectomy to Breast Conservation after Neoadjuvant Dual Target Therapy for HER2-Positive Breast Cancer in the Asian Population (2020) Breast Cancer, 27, pp. 456-463 3 false true Reference 20952085 /api/reference/20952085 4. Cancer Res, 80 (4 Suppl. l), pp. 18-29 4 false true Reference 20952084 /api/reference/20952084 5. González, A.F., Ambite, R.A., Valenti, E.L., Cubero, R.U., Gala, M.C.A., Guisado, A.M., Neopersur: Neoadjuvant Pertuzumab in a Real World Data Population in the South of Spain [abstract] (2020) Aacr 5 false true Reference 20952083 /api/reference/20952083 6. van Ramshorst, M.S., van der Voort, A., van Werkhoven, E.D., Mandjes, I.A., Kemper, I., Dezentjé, V.O., Neoadjuvant Chemotherapy with or without Anthracyclines in the Presence of Dual HER2 Blockade for HER2-Positive Breast Cancer (TRAIN-2): a Multicentre, Open-Label, Randomised, Phase 3 Trial (2018) Lancet Oncol, 19, pp. 1630-1640 6 false true Reference 20952082 /api/reference/20952082 7. Ishii, K., Morii, N., Yamashiro, H., Pertuzumab in the Treatment of HER2-Positive Breast Cancer: an Evidence-Based Review of its Safety, Efficacy, and Place in Therapy (2019) Core Evid, 14, pp. 51-70 7 false true Reference 20952081 /api/reference/20952081 8. Hurvitz, S.A., Martin, M., Symmans, W.F., Jung, K.H., Huang, C.-S., Thompson, A.M., Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy versus Trastuzumab Emtansine Plus Pertuzumab in Patients with HER2-Positive Breast Cancer (KRISTINE): a Randomised, Open-Label, Multicentre, Phase 3 Trial (2018) Lancet Oncol, 19, pp. 115-126 8 false true Reference 20952080 /api/reference/20952080 9. Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., Pertuzumab Plus Trastuzumab in Combination with Standard Neoadjuvant Anthracycline-Containing and Anthracycline-free Chemotherapy Regimens in Patients with HER2-Positive Early Breast Cancer: a Randomized Phase II Cardiac Safety Study (TRYPHAENA) (2013) Ann Oncol, 24, pp. 2278-2284 9 false true Reference 20952079 /api/reference/20952079 10. Samiei, S., van Nijnatten, T.J.A., de Munck, L., Keymeulen, K.B.M.I., Simons, J.M., Kooreman, L.F.S., Correlation between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases after Neoadjuvant Systemic Therapy (2020) Ann Surg, 271 (3), pp. 574-580 10 false true Reference 20952078 /api/reference/20952078 11. Fasching, P.A., Hartkopf, A.D., Gass, P., Häberle, L., Akpolat-Basci, L., Hein, A., Efficacy of Neoadjuvant Pertuzumab in Addition to Chemotherapy and Trastuzumab in Routine Clinical Treatment of Patients with Primary Breast Cancer: a Multicentric Analysis (2019) Breast Cancer Res Treat, 173 (2), pp. 319-328 11 false true Reference 20952077 /api/reference/20952077 12. Beitsch, P., Whitworth, P., Baron, P., Rotkis, M.C., Mislowsky, A.M., Richards, P.D., Pertuzumab/trastuzumab/CT versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) (2017) Ann Surg Oncol, 24, pp. 2539-2546 12 false true Reference 20952076 /api/reference/20952076 13. Horvath, Z., Boer, K., Dank, M., Zs, K., Kocsis, J., Kover, E., [Systemic Therapy of Breast Cancer: Practice Guideline] (2016) Magy Onkol, 60 (3), pp. 241-257 13 false true Reference 20952075 /api/reference/20952075 14. Blumenthal, G.M., Scher, N.S., Cortazar, P., Chattopadhyay, S., Tang, S., Song, P., First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer (2013) Clin Cancer Res, 19 (18), pp. 4911-4916 14 false true Reference 20952074 /api/reference/20952074 15. Gianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., 5-year Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients with Locally Advanced, Inflammatory, or Early-Stage HER2-Positive Breast Cancer (NeoSphere): a Multicentre, Open-Label, Phase 2 Randomised Trial (2016) Lancet Oncol, 17 (6), pp. 791-800 15 false true Reference 20952073 /api/reference/20952073 16. Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women with Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (NeoSphere): a Randomised Multicentre, Open-Label, Phase 2 Trial (2012) Lancet Oncol, 13 (1), pp. 25-32 16 false true Reference 20952072 /api/reference/20952072 17. Gianni, L., Eiermann, W., Semiglazov, V., Lluch, A., Tjulandin, S., Zambetti, M., Neoadjuvant and Adjuvant Trastuzumab in Patients with HER2-Positive Locally Advanced Breast Cancer (NOAH): Follow-Up of a Randomised Controlled Superiority Trial with a Parallel HER2-Negative Cohort (2014) Lancet Oncol, 15 (6), pp. 640-647 17 false true Reference 20952071 /api/reference/20952071 18. Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., Neoadjuvant Chemotherapy with Trastuzumab Followed by Adjuvant Trastuzumab versus Neoadjuvant Chemotherapy Alone, in Patients with HER2-Positive Locally Advanced Breast Cancer (The NOAH Trial): a Randomised Controlled Superiority Trial with a Parallel HER2-Negative Cohort (2010) Lancet, 375 (9712), pp. 377-384 18 false true Reference 20952070 /api/reference/20952070 19. Buzdar, A.U., Ibrahim, N.K., Francis, D., Booser, D.J., Thomas, E.S., Theriault, R.L., Significantly Higher Pathologic Complete Remission Rate after Neoadjuvant Therapy with Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-positive Operable Breast Cancer (2005) J Clin Oncol, 23 (16), pp. 3676-3685 19 false true Reference 20952069 /api/reference/20952069 20. Burstein, H.J., Curigliano, G., Loibl, S., Dubsky, P., Gnant, M., Poortmans, P., Estimating the Benefits of Therapy for Early-Stage Breast Cancer: the St. Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019 (2019) Ann Oncol, 30 (10), pp. 1541-1557 20 false true Reference 20952068 /api/reference/20952068 21. Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I.T., Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up (2019) Ann Oncol, 30 (8), pp. 1194-1220 21 false true Reference 20952067 /api/reference/20952067 22. Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J.P., Wolmark, N., Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: the CTNeoBC Pooled Analysis (2014) Lancet, 384 (9938), pp. 164-172 22 false true Reference 20952066 /api/reference/20952066 23. Cain, H., Macpherson, I.R., Beresford, M., Pinder, S.E., Pong, J., Dixon, J.M., Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice (2017) Clin Oncol, 29 (10), pp. 642-652 23 false true Reference 20952065 /api/reference/20952065 24. Long-term Outcomes for Neoadjuvant versus Adjuvant Chemotherapy in Early Breast Cancer: Meta-Analysis of Individual Patient Data from Ten Randomised Trials (2018) Lancet Oncol, 19 (1), pp. 27-39 24 false true /api/publication/32049273 Boér K. et al. Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience. (2021) PATHOLOGY AND ONCOLOGY RESEARCH 1219-4956 1532-2807 27<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10048974"><a href="/gui2/?type=authors&mode=browse&sel=10048974" target="_blank">Boér K. (<span class="authorship-author-name">Boér Katalin</span> <span class="authorAux-mtmt"> Klinikai Orvostudomány</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10013805"><a href="/gui2/?type=authors&mode=browse&sel=10013805" target="_blank">Kahán Z. (<span class="authorship-author-name">Kahán Zsuzsanna</span> <span class="authorAux-mtmt"> Elméleti orvostudomány</span>) </a> </span> <span class="author-affil"><span title="Szegedi Tudományegyetem">SZTE</span>/<span title="Szent-Györgyi Albert Orvostudományi Kar">SZAOK</span>/Onkoterápiás Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10036736"><a href="/gui2/?type=authors&mode=browse&sel=10036736" target="_blank">Landherr L. (<span class="authorship-author-name">Landherr László</span> <span class="authorAux-mtmt"> sugárterápia, klinikai onkológia</span>) </a> </span> <span class="author-affil">Uzsoki Utcai Kórház</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Csőszi T. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10035708"><a href="/gui2/?type=authors&mode=browse&sel=10035708" target="_blank">Máhr K. (<span class="authorship-author-name">Máhr Károly</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Ruzsa Á. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10026959"><a href="/gui2/?type=authors&mode=browse&sel=10026959" target="_blank">Horváth Z. (<span class="authorship-author-name">Horváth Zsolt</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10038262"><a href="/gui2/?type=authors&mode=browse&sel=10038262" target="_blank">Budai B. (<span class="authorship-author-name">Budai Barna</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10060070"><a href="/gui2/?type=authors&mode=browse&sel=10060070" target="_blank">Rubovszky G. ✉ (<span class="authorship-author-name">Rubovszky Gábor</span> <span class="authorAux-mtmt"> klinikai onkológia</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Onkológiai Tanszék</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;32049273" target="_blank">Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience</a></div> <div> <span class="journal-title">PATHOLOGY AND ONCOLOGY RESEARCH</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1219-4956">1219-4956</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1532-2807">1532-2807</a>)</span>: <span class="journal-volume">27</span> <span class="page"> Paper 1609785. 9 p. </span> <span class="year">(2021)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.3389/pore.2021.1609785" target="_blank" href="https://doi.org/10.3389/pore.2021.1609785"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000651213200001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000651213200001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85106039535" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85106039535"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="34257621" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34257621&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_GREEN" title=" Green "> <a style="color:blue" title="35999" target="_blank" href="http://publicatio.bibl.u-szeged.hu/35999"> SZTE Publicatio </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pathology and Forensic Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cancer Research&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q3</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Oncology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q3</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 22</span> | Független: 22 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 19 | Scopus jelölt:&nbsp;17 | WoS/Scopus jelölt:&nbsp;21 | DOI jelölt:&nbsp;21 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;32049273&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 1 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 32049273</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">Scopus</span> </div> <div class="lastModified">Utolsó módosítás: 2025.11.03. 13:41 Nicsinger Anita (PTE ETK admin 5) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Export Date: 9 August 2021 CODEN: POREF</pre> </div></div>